Literature DB >> 16001196

Vaginal intraepithelial neoplasia: clinical-therapeutic analysis of 33 cases.

Eddie F C Murta1, Milton A Neves Junior, Luciano R F Sempionato, Marcos C Costa, Paulo J Maluf.   

Abstract

Vaginal intraepithelial neoplasia (VAIN) represents 1% of all intraepithelial neoplasia of the lower genital tract. Our aim was to study the clinical-therapeutic characteristics of patients with VAIN. A retrospective study was made of all cases of patients, who attended within the outpatient service between 1993 and 2003, with a diagnosis of VAIN. During this period, 84,293 Papanicolaou smears (triple collection) were performed and a total of 33 (50.32+/-11.5 years old) patients with VAIN were diagnosed. Among these patients, twenty-six (78.8%) were white, 17 (51.5%) were smokers, and 23 (69.6%) had undergone hysterectomy previously. The indications for hysterectomy prior to the appearance of VAIN were found in 20 cases (87%) of cervical intraepithelial or invasive neoplasia (CIN), and in two (8.6%) cases after myoma uterine. The median time elapsed between the hysterectomy and the appearance of VAIN was 41 months. Thirteen (39.4%), 11 (33.3%) cases were, respectively, VAIN II and III. Twenty-eight patients (84.8%) presented a single lesion affecting the upper third of the vagina. The commonest finding was the presence of white epithelium in 17 patients (51.5%). Ten of 16 cases submitted to topical application of 5-fluorouracil (5-FU) achieved remission. Surgery was utilized for seven patients, of whom six achieved remission and one had persistence of the lesion. We conclude that VAIN may occur in patients who have undergone hysterectomy due to benign alterations. This justifies the use of routine Papanicolaou tests. Both surgical and 5-FU treatments are efficient.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16001196     DOI: 10.1007/s00404-005-0022-1

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  6 in total

1.  Low-dose-rate definitive brachytherapy for high-grade vaginal intraepithelial neoplasia.

Authors:  Pierre Blanchard; Laurie Monnier; Isabelle Dumas; Philippe Morice; Patricia Pautier; Pierre Duvillard; Fares Azoury; Renaud Mazeron; Christine Haie-Meder
Journal:  Oncologist       Date:  2011-01-24

2.  Clinical features, treatment and outcomes of vaginal intraepithelial neoplasia in a Chinese tertiary centre.

Authors:  L Chen; D Hu; S Xu; X Wang; Y Chen; W Lv; X Xie
Journal:  Ir J Med Sci       Date:  2014-11-25       Impact factor: 1.568

3.  Prevention of K-Ras- and Pten-mediated intravaginal tumors by treatment with camptothecin-loaded PLGA nanoparticles.

Authors:  Jeremy S Blum; Caroline E Weller; Carmen J Booth; Imran A Babar; Xianping Liang; Frank J Slack; W Mark Saltzman
Journal:  Drug Deliv Transl Res       Date:  2011-10-01       Impact factor: 4.617

4.  The utility of the human papillomavirus DNA load for the diagnosis and prediction of persistent vaginal intraepithelial neoplasia.

Authors:  Kyeong A So; Jin-Hwa Hong; Jong Ha Hwang; Seung-Hun Song; Jae-Kwan Lee; Nak Woo Lee; Kyu Wan Lee
Journal:  J Gynecol Oncol       Date:  2009-12-28       Impact factor: 4.401

5.  Detection of Human Papillomavirus Infection in Patients with Vaginal Intraepithelial Neoplasia.

Authors:  Cristina Lamos; Charlotte Mihaljevic; Sebastian Aulmann; Thomas Bruckner; Christoph Domschke; Markus Wallwiener; Carmen Paringer; Herbert Fluhr; Sarah Schott; Christine Dinkic; Janina Brucker; Michael Golatta; Lisa Gensthaler; Michael Eichbaum; Christof Sohn; Joachim Rom
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

6.  Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer.

Authors:  Toshiaki Saito; Tsutomu Tabata; Hitoshi Ikushima; Hiroyuki Yanai; Hironori Tashiro; Hitoshi Niikura; Takeo Minaguchi; Toshinari Muramatsu; Tsukasa Baba; Wataru Yamagami; Kazuya Ariyoshi; Kimio Ushijima; Mikio Mikami; Satoru Nagase; Masanori Kaneuchi; Nobuo Yaegashi; Yasuhiro Udagawa; Hidetaka Katabuchi
Journal:  Int J Clin Oncol       Date:  2017-11-20       Impact factor: 3.402

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.